# LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

> **NCT04402957** · PHASE2 · COMPLETED · sponsor: **Arch Biopartners Inc.** · enrollment: 61 (actual)

## Conditions studied

- COVID
- Severe Acute Respiratory Syndrome
- Sars-CoV2
- Acute Kidney Injury
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** LSALT peptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04402957
- **Lead sponsor:** Arch Biopartners Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2021-05-27
- **Final completion:** 2022-06-02
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402957

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402957, "LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04402957. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*